A weekly discussion of all things biotech – breaking news, data, deals, and FDA actions – with a community of biotech industry leaders and experts. Join the live streams hosted by @BiotechCH, @daphnezohar, @bradloncar and @biotech1 on Twitter Spaces every Friday at 12pm ET.
The 200th episode of Biotech Hangout examines the current biotech landscape, characterized by significant market volatility and a shift toward asset-centric business models. Technical trading patterns and the influence of platform funds often decouple stock prices from fundamental value, as seen in recent fluctuations ...
The public biotech market faces a significant correction as investors rotate capital into broader healthcare subsectors, evidenced by the XBI ETF’s recent decline and a pronounced "degrossing" trend among hedge funds. Despite this volatility, the IPO market remains resilient with 28 new debuts in 2026, though M&A activ...
Public biotech markets remain resilient, with the XBI index significantly outperforming broader healthcare and tech benchmarks despite recent volatility. Strategic partnerships define current industry momentum, highlighted by the Regeneron-Sanofi collaboration extension and AstraZeneca’s $2 billion equity investment in...
The biotech sector faces a complex landscape defined by shifting market dynamics, evolving regulatory policies, and significant clinical trial readouts. While small-cap performance has pressured long-short funds, the IPO market remains robust, signaling continued investor interest. Policy discussions center on Most Fav...
The biotech industry currently navigates a complex landscape defined by shifting capital flows, the integration of AI, and evolving regulatory environments. While AI agents demonstrate potential for both innovation and security risks, the sector remains focused on therapeutic development rather than broader existential...
The biotech sector faces significant volatility as rising interest rates and energy prices weigh on the XBI index, shifting focus back to macroeconomic sensitivity. Regulatory stability emerges with the permanent appointments of Michael Davis to CDER and Kareem to CBER, signaling a transition toward more predictable ag...
Biotech capital markets remain resilient, with significant M&A activity offsetting policy uncertainty and a shifting IPO landscape. Big Pharma’s patent cliff continues to drive aggressive deal-making, even as acquisition premiums compress. Clinical developments dominate the sector, highlighted by Moderna’s positive mel...
Public biotech markets remain healthy but increasingly discerning, as investors prioritize companies with robust clinical data over broad sector rallies. Biotech is emerging as a potential hedge against AI-related market volatility, though the sector remains highly sensitive to individual data readouts. Recent clinical...
The biotech industry faces a shifting landscape defined by market volatility, a surge in IPO activity, and evolving regulatory pressures. Recent speculation regarding potential mega-mergers, such as the rumored AstraZeneca and Bristol Myers deal, highlights concerns over capital efficiency and the potential for reduced...
Biotech sector performance remains volatile, with the XBI index experiencing recent pressure despite strong year-to-date gains compared to broader market indices. Robust M&A activity continues to drive the industry, fueled by large pharmaceutical companies seeking to address patent expirations and revenue gaps. AI inte...
Biotech capital markets are witnessing a shift toward earlier-stage IPOs and an increase in reverse mergers, signaling rising risk tolerance despite a departure from the peak valuations of 2021. While companies like Scribe and Mentari leverage these pathways to access public capital, the long-term durability of these s...
Biotech industry leaders analyze recent market volatility and shifting regulatory landscapes, specifically focusing on the FDA's potential retrenchment regarding Complete Response Letter (CRL) transparency and the implications of leadership changes. The discussion highlights the integration of AI in drug discovery, not...
The biotech sector is currently experiencing a robust rally, fueled by strong fundamentals and a more permissive FDA regulatory environment. While M&A remains a primary driver of value, a shift is occurring as some companies prioritize long-term independence to build sustainable, revenue-generating businesses. Cross-bo...
Biotech market performance remains resilient, with the XBI index outperforming the S&P 500 year-to-date despite recent volatility. The IPO landscape shows signs of recovery, characterized by high-quality, data-driven offerings and a growing trend of dual-track processes where private companies weigh public listings aga...
Biotech industry performance currently faces headwinds as capital migrates toward AI-driven sectors, though long-term sector recovery remains supported by robust M&A activity. Legislative proposals like the Biotech Investment National Security Act threaten to restrict global collaboration and limit U.S. patient access ...
The biotech industry is experiencing a resurgence in IPO activity, characterized by a shift toward late-stage clinical assets that suggest a maturing, albeit cautious, market. Central to current industry discourse is the tension between cost-efficient global outsourcing and the national security implications of offshor...
The biotech industry is experiencing a paradigm shift as China evolves from a low-cost development partner into a source of high-quality, validated innovation, forcing U.S. firms to rethink their competitive strategies. While AI-driven platforms like Isomorphic Labs attract massive capital, the transition from computat...
The biotech industry faces a complex landscape defined by record-breaking secondary offerings, shifting investor appetites, and significant regulatory volatility. While strong clinical data continues to drive capital inflows, the rapid pace of M&A—highlighted by the acquisition of Candid Therapeutics—underscores the st...
The biotech sector maintains positive year-to-date performance, with the XBI index outperforming broader markets despite recent volatility. The IPO window remains open for high-quality, long-incubated companies, evidenced by ten successful debuts raising $3.2 billion. M&A activity continues to accelerate, driven by Eli...
Follow this podcast in Podwise
Sign in to get AI summaries, transcripts and mind maps for any episode, including new ones.
